tients and 62 peritoneal-dialysis patients at Siriraj hospital. Utility scores and the correlation coefficient with KDQOL-36 were calculated. Percentages of respondents with the ceiling and floor effects were compared for each of the different measurement tools. RESULTS: Patient samples had a mean age of 60.20Ϯ14.84 years. Mean duration of dialysis were 7.44Ϯ5.42 years for hemodialysis patients, and 1.82Ϯ1.22 years for peritoneal-dialysis patients. The mean SF-6D score (0.783Ϯ0.164) was significantly higher than EQ-5D (UK: 0.752Ϯ0.309, Thai: 0.691Ϯ0.314), and VAS (0.666Ϯ0.196) scores. Most of the kidney specific dimensions were better correlated with SF-6D than EQ-5D (UK and Thai preference weight) and VAS scores. Ceiling effects were observed in the EQ-5D concerning both UK and Thai preference weight, due to the fact that the EQ-5D differentiates less in the better health states, whereas the floor effects were not clearly observed in any instrument tools. CONCLUSIONS: SF-6D presented better correlation with kidney specific scales while the responsiveness of EQ-5D utility scores was poor. One explanation might be a ''ceiling effect'' of the EQ-5D. These findings implied that SF-6D utility scores could reflect HRQoL status of dialysis patients better than EQ-5D and VAS. 
RESEARCH POSTER PRESENTATIONS -SESSION IV RESEARCH ON METHODS STUDIES RESEARCH ON METHODS -Clinical Outcomes Methods

PRM1 COMPLIANCE ON THE CONSOLIDATED STANDARDS OF REPORTING TRIALS (CONSORT) GUIDELINES IN RANDOMIZED CONTROLLED TRIALS
Each article was reviewed by two independent investigators based on the reporting criteria recommended by the CONSORT statement. Exclusion criteria included non-randomized control studies, and studies not including intervention or control group. RESULTS: The study identified 129 published articles using explicit criteria on Medline search. A total of 73 randomized controlled trials met the inclusion criteria. Of 73 studies, 55 (75.34%) articles included the CONSORT diagram. A comprehensive depiction of the CON-SORT guidelines will be made and detail descriptions on the compliances will be presented by journal types during the presentation. CONCLUSIONS: Randomized controlled trials published in the top 10 general medicine journals and the top 5 infectious diseases journals in 2010 contain significant deficiencies in reporting the CONSORT flow chart. The clarity and the completeness of a study could be improved if the CONSORT statement is followed as prescribed. 
PRM2 NETWORK META-ANALYSIS OF INDIVIDUAL AND AGGREGATE LEVEL DATA
OBJECTIVES:
Network meta-analysis is often performed with aggregate level data (AD). A challenge with meta-regression models using AD is that the association between a patient level covariate and relative treatment effects of the compared interventions at the study level may not reflect the individual level effect-modification. In this paper, non-linear network meta-analysis models for combining individual patient data (IPD) and AD are presented to reduce bias and uncertainty of treatment effects in the presence of heterogeneity due to patient characteristics. METHODS: The first method uses the same model form for IPD and AD. With the second method, the model for AD is obtained by integrating an underlying IPD model over the joint within-study distribution of covariates. With a simple simulation study the two modeling approaches are compared. RESULTS: Having IPD for a subset of studies improves estimation of treatment effects with network metaanalysis in the presence of patient level heterogeneity and inconsistency. Of the two proposed non-linear models for combining IPD and AD, the second approach seems less affected by bias. Additional studies, however, are needed to assess the value of both methods. CONCLUSIONS: Overall, for network meta-analysis it is recommended to use IPD when available, rather than treating all studies as AD. 
PRM3 THE ENSEMBLE MINIMUM DATASET: A NEW INSTRUMENT TO EXPLORE HETEROGENEITY OF TREATMENT EFFECT
OBJECTIVES:
To develop an instrument that identifies patient groups likely to have differing responses to treatment, we tested candidate measures thought to discriminate differences among patients in 4 disease cohorts: type 2 diabetes (T2D), knee osteoarthritis (OA), ischemic heart disease (IHD) and heart failure (HF). METHODS: Eligible patients identified from claims data were sent a survey including 17 scales hypothesized to comprise 4 domains (health profile, personality, behavior, life context). Proxies for treatment response were patient-reported global impression of disease severity (PGIS), global impression of improvement (PGII), and administrative claims health care utilization (HCU). Variability (SD) and internal consistency (Cronbach's alpha) of the scales were examined, as was discriminant validity against strata of PGIS, PGII and HCU. Conceptual overlap, correlations among scales, and factor loading within and across domains were examined. Scales with desirable properties were included in the final instrument. Discriminant validity of proposed domains was analyzed by ANOVA adjusted for age and gender. Multiple regression models were used to assess the associations between the proposed domains and outcomes. RESULTS: A total of 723 T2D patients, 682 knee OA patients, 632 IHD patients, and 588 HF patients completed the survey. The initial instrument was refined to 7 scales across 3 domains. The health profile domain significantly discriminated 100% of the strata across disease cohorts (each PϽ0.001). Personality and behavior domains also discriminated strata well (75% and 50%, respectively). Alone, the health profile significantly discriminated strata across disease cohorts in multivariate analyses (each P Ͻ0.001). In models including all 3 domains, the health profile remained the most important contributor. CONCLUSIONS: The final ENSEMBLE MDS instrument discriminated among patients with varied diseases; the health profile provided much of the ability to discriminate. Further research is needed to assess the instrument's potential to predict health state changes due to trial interventions. 
PRM4 ENHANCING THE HEALTH ECONOMIC VALUE OF RETROSPECTIVE AND PROSPECTIVE REAL-WORLD STUDIES WITH PHARMACOGENOMIC TESTING: OPPORTUNITIES AND CHALLENGES ASSOCIATED WITH AN INTEGRATED PERSONALIZED MEDICINE APPROACH
OBJECTIVES:
A better understanding of a patient's genetic make-up through pharmacogenomic testing can help achieve improved and more predictable patient outcomes, often at equal or lower total treatment cost. Stakeholders including physicians, payers and patients alike can benefit from real-world data that identify, a priori, the sub-groups of patients for whom treatments are likely to be more cost-effective. METHODS: Retrospective and prospective case study designs within which pharmacogenomic testing has been integrated are presented. Design parameters are described and opportunities and challenges alongside strategies for resolution are delineated. RESULTS: As the genetic make-up of a patient does not change, pharmacogenomic testing can be done at any point in time and paired with historical and/or newly collected patient level data. Retrospective studies are highly efficient as they do not require costly longitudinal follow-up, whereas prospective studies including registries offer the opportunity to augment pharmacogenomic and other study data with patient and physician reported outcomes not otherwise available in the medical chart. Main challenges associated with either approach include optimizing the patient informed consent process, streamlining the logistics associated with pharmacogenomic testing and storage in the usual A159 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
